Home Article Viemed sees ongoing organic growth

Viemed sees ongoing organic growth

Viemed sees ongoing organic growth

Specialty Providers

Default Author Head Shot

By HME News Staff

Updated 9:21 AM CDT, Thu August 7, 2025

Casey HoytLAFAYETTE, La. – Viemed Healthcare remained “on track” during the second quarter of 2025, reporting revenue of $63.1 million, an increase of 14.7% over the same period in 2024. 

Adjusted EBITDA for the quarter totaled $14.3 million, an 11.5% increase.  

"The solid execution of our vent and sleep businesses - together with continued leveraging of expenses - produced second quarter results that met our expectations and kept us on track for our organic growth targets in 2025,” said CEO Casey Hoyt. “The addition of Lehan's enabled us to increase our full year revenue and adjusted EBITDA guidance, and the early progress from our integration plans reinforces the confidence we have in accelerating their growth. The strong operating cash flow during the quarter continues to contribute to our rock-solid balance sheet. We have successfully deployed that capital into share repurchases and have remained active to date with that program in the third quarter." 

Viemed on July 1 closed on its previously announced acquisition of Lehan's Medical Equipment for a base purchase price of $26 million. 

Other highlights from the quarter: 

  • The company increased its ventilator patient count to 12,152 as of June 30, an increase of 11.4% over June 30, 2024. 

  • It increased its PAP therapy patient count to 26,260 as of June 30, an increase of 51.4%, and its sleep resupply patient count was 25,246, an increase of 25.1% over June 30, 2024. 

Viemed also updated its full year 2025 guidance to: 

  • Net revenue for the year ending Dec. 31, 2025, is expected to be in the range of $271 million to $277 million, increased from the prior range of $256 million to $265 million. The increase in the range is primarily related to the inclusion of Lehan's anticipated results for the second half of 2025. 

  • Adjusted EBITDA for the year ending Dec. 31, 2025, is expected to be in the range of $59 million to $62 million, increased from the prior range of $55 million to $58 million. The increase in the range is primarily related to the inclusion of Lehan's anticipated results for the second half of 2025.

Comments

To comment on this post, please log in to your account or set up an account now.